Num­ber 7? Cel­gene part­ner BeiGene joins the crowd with stel­lar PD-1/L1 da­ta from a piv­otal test

Get ready for the sec­ond wave of PD-1/L1 check­point in­hibitors.

BeiGene $BGNE an­nounced just ahead of the start of the week in Bei­jing that their PD-1 tislelizum­ab — part­nered with Cel­gene $CELG — scored stel­lar da­ta in a small Phase II tri­al for clas­si­cal Hodgkin’s lym­phoma among pa­tients who had ei­ther failed or couldn’t take au­tol­o­gous stem cell trans­plan­ta­tion. This is their first piv­otal tri­al, and it un­der­scores why Cel­gene inked a $1.4 bil­lion deal to buy in­to the drug — which may end up as the 7th new check­point to hit the glob­al mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER